130 related articles for article (PubMed ID: 27614350)
21. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.
van der Burg SH; Visseren MJ; Brandt RM; Kast WM; Melief CJ
J Immunol; 1996 May; 156(9):3308-14. PubMed ID: 8617954
[TBL] [Abstract][Full Text] [Related]
22. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
23. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
[TBL] [Abstract][Full Text] [Related]
24. The recognition of a viral antigenic moiety by class I MHC-restricted cytolytic T lymphocytes is limited by the availability of the endogenously processed antigen.
Milligan GN; Morrison LA; Gorka J; Braciale VL; Braciale TJ
J Immunol; 1990 Nov; 145(10):3188-93. PubMed ID: 1700000
[TBL] [Abstract][Full Text] [Related]
25. Long-lasting cross-presentation of tumor antigen in human DC.
Faure F; Mantegazza A; Sadaka C; Sedlik C; Jotereau F; Amigorena S
Eur J Immunol; 2009 Feb; 39(2):380-90. PubMed ID: 19130478
[TBL] [Abstract][Full Text] [Related]
26. Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.
Hattotuwagama CK; Doytchinova IA; Flower DR
Methods Mol Biol; 2007; 409():227-45. PubMed ID: 18450004
[TBL] [Abstract][Full Text] [Related]
27. Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cells.
Shetty V; Nickens Z; Testa J; Hafner J; Sinnathamby G; Philip R
J Proteomics; 2012 Jun; 75(11):3270-90. PubMed ID: 22504797
[TBL] [Abstract][Full Text] [Related]
28. Thermostability profiling of MHC-bound peptides: a new dimension in immunopeptidomics and aid for immunotherapy design.
Jappe EC; Garde C; Ramarathinam SH; Passantino E; Illing PT; Mifsud NA; Trolle T; Kringelum JV; Croft NP; Purcell AW
Nat Commun; 2020 Dec; 11(1):6305. PubMed ID: 33298915
[TBL] [Abstract][Full Text] [Related]
29. Lost in the crowd: identifying targetable MHC class I neoepitopes for cancer immunotherapy.
Wilson EA; Anderson KS
Expert Rev Proteomics; 2018 Dec; 15(12):1065-1077. PubMed ID: 30408427
[TBL] [Abstract][Full Text] [Related]
30. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
31. TransLnc: a comprehensive resource for translatable lncRNAs extends immunopeptidome.
Lv D; Chang Z; Cai Y; Li J; Wang L; Jiang Q; Xu K; Ding N; Li X; Xu J; Li Y
Nucleic Acids Res; 2022 Jan; 50(D1):D413-D420. PubMed ID: 34570220
[TBL] [Abstract][Full Text] [Related]
32. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
33. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response.
Shetty V; Sinnathamby G; Nickens Z; Shah P; Hafner J; Mariello L; Kamal S; Vlahović G; Lyerly HK; Morse MA; Philip R
J Proteomics; 2011 May; 74(5):728-43. PubMed ID: 21362506
[TBL] [Abstract][Full Text] [Related]
34. Integrated modeling of the major events in the MHC class I antigen processing pathway.
Dönnes P; Kohlbacher O
Protein Sci; 2005 Aug; 14(8):2132-40. PubMed ID: 15987883
[TBL] [Abstract][Full Text] [Related]
35. Epitope distribution in ordered and disordered protein regions. Part B - Ordered regions and disordered binding sites are targets of T- and B-cell immunity.
Pavlović MD; Jandrlić DR; Mitić NS
J Immunol Methods; 2014 May; 407():90-107. PubMed ID: 24726865
[TBL] [Abstract][Full Text] [Related]
36. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro.
Bakker AB; Marland G; de Boer AJ; Huijbens RJ; Danen EH; Adema GJ; Figdor CG
Cancer Res; 1995 Nov; 55(22):5330-4. PubMed ID: 7585596
[TBL] [Abstract][Full Text] [Related]
37. Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1.
Minev BR; Chavez FL; Dudouet BM; Mitchell MS
Eur J Immunol; 2000 Aug; 30(8):2115-24. PubMed ID: 10940901
[TBL] [Abstract][Full Text] [Related]
38. POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties.
Tung CW; Ho SY
Bioinformatics; 2007 Apr; 23(8):942-9. PubMed ID: 17384427
[TBL] [Abstract][Full Text] [Related]
39. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
[TBL] [Abstract][Full Text] [Related]
40. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
Engelhard VH; Bullock TN; Colella TA; Mullins DW
Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
